Cypress Asset Management Inc Editas Medicine, Inc. Transaction History

Cypress Asset Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	SELL	$18.19 - $31.79 $124,146 - $216,966	-6,825 Closed	0 $0
Q3 2018 Oct 19, 2018	SELL	$27.65 - $38.39 $4,424 - $6,142	-160 Reduced 2.29%	6,825 $217,000
Q2 2018 Jul 27, 2018	SELL	$31.4 - $41.01 $1,256 - $1,640	-40 Reduced 0.57%	6,985 $250,000
Q1 2018 May 14, 2018	BUY	$29.84 - $44.08 $209,626 - $309,662	7,025 New	7,025 $233,000

247

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $163M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Cypress Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cypress Asset Management Inc with notifications on news.